Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D1097 | sofalcone

Molecular Formula C27H30O6
Molecular Weight 450.5
Structure
State solid

Toxicity Dose Time Species Model Method Action Positive criterion Reference
MEMBRANE POTENTIAL 24.64±1.67 human qHTS-HepG2 MMP assay decrease IC50 163
MEMBRANE POTENTIAL 17.34 human HepG2 MMP assay decrease IC50 163
MEMBRANE POTENTIAL 19.54±2.25 rat hepatocytes MMP assay decrease IC50 163

Organism Test type Route Dose (normalized dose) Effect Source
mouse LD50 oral > 10gm/kg (10000mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 61, 1982.
rat LD50 subcutaneous 3900mg/kg (3900mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 61, 1982.
rat LD50 oral > 10gm/kg (10000mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 61, 1982.
rat LD50 intraperitoneal 1680mg/kg (1680mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 61, 1982.
mouse LD50 intraperitoneal > 4gm/kg (4000mg/kg) United States Patent Document. Vol. #4221810,
mouse LD50 intravenous 131mg/kg (131mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 61, 1982.
rat LD50 intravenous 105mg/kg (105mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 61, 1982.
mouse LD50 intraperitoneal 609mg/kg (609mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 61, 1982.
dog LD50 oral > 20gm/kg (20000mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 61, 1982.
mouse LD50 subcutaneous 1130mg/kg (1130mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 61, 1982.


  • (5-((3-Methyl-2-butenyl)oxy)-2-(p-((3-methyl-2-butenyl)oxy)cinnamoyl)phenoxy)acetic acid (E)-2-(5-(3-methylbut-2-enyloxy)-2-(3-(4-(3-methylbut-2-enyloxy)phenyl)acryloyl)phenoxy)acetic acid ({5-[(3-methylbut-2-en-1-yl)oxy]-2-[(2E)-3-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}prop-2-enoyl]phenyl}oxy)acetic acid
    153175-87-2 2'-Carboxymethoxy-4,4'-bis(3-methyl-2-butenyloxy)chalcone 2'-carboxymethoxy-4,4'-bis(3-methylbut-2-enyloxy)chalcone sofalcone
    2-[5-(3-methylbut-2-enoxy)-2-[(E)-3-[4-(3-methylbut-2-enoxy)phenyl]-1-oxoprop-2-enyl]phenoxy]acetic acid 2-[5-(3-methylbut-2-enoxy)-2-[(E)-3-[4-(3-methylbut-2-enoxy)phenyl]prop-2-enoyl]phenoxy]ethanoic acid 2-carboxymethoxy-4,4'-bis(3-methyl-2-butenyloxy)chalcone
    2-{5-[(3-methylbut-2-en-1-yl)oxy]-2-(3-{4-[(3-methylbut-2-en-1- yl)oxy]phenyl}prop-2-enoyl)phenoxy}acetic acid 2-{5-[(3-methylbut-2-en-1-yl)oxy]-2-[(2E)-3-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}prop-2-enoyl]phenoxy}acetic acid 2B668TJX8E
    506S496 64506-49-6 A834791
    AC-22578 AKOS015895236 Acetic acid, (5((3-methyl-2-butenyl)oxy)-2-(3-(4-((3-methyl-2-butenyl)oxy)phenyl)-1-oxo-2-propenyl)phenoxy)-
    Acetic acid, 2-(5-((3-methyl-2-buten-1-yl)oxy)-2-((2E)-3-(4-((3-methyl-2-buten-1-yl)oxy)phenyl)-1-oxo-2-propen-1-yl)phenoxy)- Acetic acid,[5-[(3-methyl-2-butenyl)oxy]-2-[3-[4-[(3-methyl-2-butenyl)oxy]phenyl]-1-oxo-2-propenyl]phenoxy]-; BCP12009
    BRN 2191482 C27H30O6 CAS-64506-49-6
    CHEBI:135732 CHEMBL1441961 CS-7893
    D01956 DB05197 DSSTox_CID_3586
    DSSTox_GSID_23586 DSSTox_RID_77093 DTXSID5023586
    EBD45865 HY-B2184 Isoprenyl chalcone
    KS-1141 LS-12474 NCGC00159481-02
    NCGC00159481-03 Q15410187 SC-13787
    SCHEMBL24786 SU 88 SU-88
    Sofaclone Sofalcona Sofalcona [Spanish]
    Sofalcone (JAN) Sofalcone [INN:JAN] Sofalcone [INN]
    Sofalcone [JAN] Sofalcone [MART.] Sofalcone [MI]
    Sofalcone [WHO-DD] Sofalconum Sofalconum [Latin]
    Solon Solon (TN) Tox21_111705
    Tox21_111705_1 UNII-2B668TJX8E ZINC3831462
    s5450 sofalcone {5-[(3-Methyl-2-butenyl)oxy]-2-{p-[(3-methyl-2-butenyl)oxy]cinnamoyl}phenoxy}acetic acid

    DrugBank DB05197
    CAS Number 13190-97-1, 153175-87-2, 64506-49-6
    PubChem Compound 5282219
    KEGG Drug D01956
    ChEBI 135732